➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Patent: 9,822,174

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,822,174
Title:Anti-VEGF antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same
Abstract: A novel anti-vascular endothelial growth factor (VEGF) antibody having a strong binding affinity for VEGF and capable of inhibiting in vivo tumor growth and a composition for the treatment of cancer, containing the same. The antibody shows a remarkable binding property to human and mouse VEGF, suppresses the proliferation and permeability of a human umbilical vein endothelial cell (HUVEC) and inhibits tumor growth, and thus can be useful as an antibody for the treatment of cancer.
Inventor(s): Doh; Hyounmie (Seoul, KR), Kim; Byong Moon (Seoul, KR), Kim; Chae Young (Suwon-si, KR), Lee; Sung-Hee (Seoul, KR), Kim; Dong-Hyeon (Daejeon, KR), Kim; Yoo-jin (Yongin-si, KR), Lee; Dongsop (Yongin-si, KR), Han; Kyung Mi (Yongin-si, KR), Song; Dongsup (Suwon-si, KR), Jung; Eun-ee (Seoul, KR), Lee; Jinseok (Suwon-si, KR), Seung; Woo Jin (Seoul, KR), Hwang; Kyusang (Seoul, KR)
Assignee: DONG-A SOCIO HOLDINGS CO., LTD. (Seoul, KR) DONG-A ST CO., LTD (Seoul, KR)
Application Number:14/893,813
Patent Claims:see list of patent claims

Details for Patent 9,822,174

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial DONG-A SOCIO HOLDINGS CO., LTD. (Seoul, KR) DONG-A ST CO., LTD (Seoul, KR) 2033-05-31 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.